tldrdaily.news logo

FDA Issues Warning to Novartis Over Misleading TV Ad for Breast Cancer Drug

1 min read
Source: Endpoints News
FDA Issues Warning to Novartis Over Misleading TV Ad for Breast Cancer Drug
Photo: Endpoints News
TL;DR Summary

The FDA issued an untitled letter to Novartis, criticizing a TV commercial for the breast cancer drug Kisqali as containing "false or misleading" information. The ad, which featured a "Long Live" tagline and ran from 2022 to September 2023, was flagged for potentially giving metastatic breast cancer patients an exaggerated impression of the drug's effectiveness in treating their condition and symptoms.

Topics:health#breast-cancer-drug#fda#healthcarepharmaceuticals#kisqali#novartis#tv-ad
Share this article
  1. Novartis' TV ad for breast cancer drug Kisqali draws untitled letter from FDA  Endpoints News
  2. FDA scolds Novartis over a misleading TV ad for a breast cancer treatment  STAT

Reading Insights

Total Reads

0

Unique Readers

1

Time Saved

0 min

vs 1 min read

Condensed

56%

140 → 61 words

Want the full story? Read the original article

Read on Endpoints News